Profile data is unavailable for this security.
About the company
Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
- Revenue in USD (TTM)0.00
- Net income in USD-54.70m
- Incorporated1995
- Employees37.00
- LocationSavara Inc6836 BEE CAVE ROADBUILDING 3, SUITE 201AUSTIN 78746United StatesUSA
- Phone+1 (512) 614-1848
- Fax+1 (858) 552-0876
- Websitehttp://savarapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNDL Inc | 665.35m | -123.06m | 643.41m | 2.52k | -- | 0.7316 | -- | 0.967 | -0.4724 | -0.4852 | 2.57 | 3.38 | 0.5995 | 5.29 | 36.58 | 264,448.90 | -11.34 | -24.44 | -12.28 | -27.94 | 24.17 | 22.49 | -18.92 | -62.17 | 2.69 | -9.29 | 0.1196 | -- | 27.63 | -- | 49.83 | -- | -- | -- |
| Lyell Immunopharma Inc | 68.00k | -228.34m | 647.54m | 224.00 | -- | 1.07 | -- | 9,522.64 | -0.9057 | -0.9057 | 0.0003 | 2.37 | 0.00009 | -- | -- | 303.57 | -29.00 | -- | -30.21 | -- | -- | -- | -335,794.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Prime Medicine Inc | 0.00 | -198.13m | 648.16m | 234.00 | -- | 3.95 | -- | -- | -2.17 | -2.17 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -84.13 | -- | -- | -- | -- | -- | -- | -85.97 | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
| Mind Medicine (MindMed) Inc | 0.00 | -95.73m | 662.66m | 57.00 | -- | 4.85 | -- | -- | -2.45 | -2.45 | 0.00 | 1.90 | 0.00 | -- | -- | 0.00 | -65.01 | -- | -78.34 | -- | -- | -- | -- | -- | -- | -- | 0.1531 | -- | -- | -- | -68.55 | -- | -- | -- |
| Phibro Animal Health Corp | 982.01m | 14.80m | 666.28m | 1.92k | 45.02 | 2.46 | 13.42 | 0.6785 | 0.3654 | 0.3654 | 24.24 | 6.69 | 1.02 | 2.37 | 6.49 | 511,465.60 | 1.53 | 5.46 | 1.87 | 6.83 | 30.43 | 31.41 | 1.51 | 5.11 | 1.60 | 2.50 | 0.6369 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Novavax Inc | 983.71m | -545.06m | 668.32m | 1.54k | -- | -- | -- | 0.6794 | -5.53 | -5.53 | 9.42 | -5.14 | 0.485 | 8.76 | 5.18 | 637,527.60 | -26.88 | -46.06 | -- | -269.57 | 65.10 | -- | -55.41 | -75.94 | 0.6741 | -38.31 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Castle Biosciences Inc | 250.73m | -30.80m | 673.89m | 610.00 | -- | 1.67 | -- | 2.69 | -1.15 | -1.15 | 9.28 | 14.59 | 0.5664 | 8.01 | 7.12 | 411,024.60 | -6.96 | -9.43 | -7.48 | -10.17 | 80.58 | 80.58 | -12.28 | -28.46 | 9.02 | -- | 0.0243 | -- | 60.38 | 57.35 | 14.41 | -- | 117.94 | -- |
| Mineralys Therapeutics Inc | 0.00 | -71.90m | 682.43m | 28.00 | -- | 2.35 | -- | -- | -1.79 | -1.79 | 0.00 | 5.86 | 0.00 | -- | -- | 0.00 | -39.28 | -- | -41.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -141.28 | -- | -- | -- |
| enGene Holdings Inc | 0.00 | -106.80m | 683.12m | 33.00 | -- | 5.76 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
| Savara Inc | 0.00 | -54.70m | 683.97m | 37.00 | -- | 4.87 | -- | -- | -0.3424 | -0.3424 | 0.00 | 1.02 | 0.00 | -- | -- | 0.00 | -34.47 | -36.86 | -36.36 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.158 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
| Hillevax Inc | 0.00 | -123.57m | 686.15m | 90.00 | -- | 2.48 | -- | -- | -3.04 | -3.04 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.35 | -- | -39.90 | -- | -- | -- | -- | -- | -- | -- | 0.0868 | -- | -- | -- | 22.68 | -- | -- | -- |
| Dianthus Therapeutics Inc | 2.83m | -43.56m | 702.02m | 53.00 | -- | 2.10 | -- | 248.41 | -10.77 | -10.77 | 0.4429 | 11.40 | 0.0173 | -- | -- | 53,320.75 | -26.72 | -41.40 | -28.86 | -44.70 | -- | -- | -1,541.22 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| Wave Life Sciences Ltd | 113.31m | -57.51m | 703.33m | 266.00 | -- | 17.29 | -- | 6.21 | -0.5397 | -0.5397 | 1.07 | 0.3987 | 0.5378 | -- | -- | 425,958.70 | -27.30 | -56.98 | -70.41 | -102.38 | -- | -- | -50.76 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
| AnaptysBio Inc | 17.16m | -163.62m | 704.00m | 117.00 | -- | 7.78 | -- | 41.03 | -6.07 | -6.07 | 0.6372 | 3.31 | 0.0323 | -- | 4.15 | 146,641.00 | -30.79 | -18.08 | -32.75 | -18.96 | -- | -- | -953.66 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
| Cogent Biosciences Inc | 0.00 | -192.41m | 723.79m | 164.00 | -- | 3.30 | -- | -- | -2.40 | -2.40 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -62.65 | -49.53 | -70.07 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Data as of May 07 2024. Currency figures normalised to Savara Inc's reporting currency: US Dollar USD
32.52%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Jennison Associates LLCas of 31 Mar 2024 | 8.84m | 6.40% |
| Adage Capital Management LPas of 31 Dec 2023 | 7.64m | 5.53% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 6.65m | 4.81% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 6.26m | 4.53% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 5.83m | 4.22% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.33m | 1.68% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 2.06m | 1.49% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.82m | 1.32% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.77m | 1.28% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2023 | 1.75m | 1.27% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
